<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The roles of cholecystokinin 2 receptor (CCK2R) in numerous physiologic processes in the gastrointestinal tract and central <z:mp ids='MP_0008912'>nervous</z:mp> system are well documented </plain></SENT>
<SENT sid="1" pm="."><plain>There has been some evidence that CCK2R alterations play a role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, but the functional significance of these alterations for <z:mp ids='MP_0002006'>tumorigenesis</z:mp> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We have identified six mutations in CCK2R among a panel of 140 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and 44 <z:hpo ids='HP_0012126'>gastric cancers</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We show that these mutations increase receptor activity, activate multiple downstream signaling pathways, increase cell migration, and promote <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Our findings suggest that <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in CCK2R may promote <z:mp ids='MP_0002006'>tumorigenesis</z:mp> through deregulated receptor activity and highlight the importance of evaluating CCK2R inhibitors to block both the <z:mpath ids='MPATH_458'>normal</z:mpath> and mutant forms of the receptor </plain></SENT>
</text></document>